Pricing Log in Create free account

Nuvation Bio Inc. (NUVB) vs Ocular Therapeutix, Inc. (OCUL)

Nuvation Bio Inc. and Ocular Therapeutix, Inc. are both Biotechnology companies. Nuvation Bio Inc. and Ocular Therapeutix, Inc. are of similar size ($1.7B and $1.6B). Nuvation Bio Inc. grew revenue faster over the last twelve months: 1,083.6% against −8.14%. Nuvation Bio Inc. has the higher net margin (−88.2% vs −579.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Nuvation Bio Inc. leads on 13 and Ocular Therapeutix, Inc. on 3.

Valuation

Metric NUVB OCUL Biotechnology median
P/E n/m n/m 8.50
P/S 9.13 29.69 9.71
P/B 6.11 2.97 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 6.71 19.59 9.21
Earnings yield (9.76%) (20.67%) (33.15%)
Free cash flow yield (7.79%) (16.51%) (25.50%)

Profitability

Metric NUVB OCUL Biotechnology median
Gross margin 88.18% 87.11% 65.16%
Operating margin (81.00%) (603.04%) 0.00%
Net margin (88.19%) (579.10%) 0.00%
Free cash flow margin (71.17%) (490.07%) 0.00%
Return on equity (47.81%) (72.99%) (56.36%)
Return on assets (21.53%) (53.70%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NUVB OCUL Biotechnology median
Revenue growth (TTM) 1,083.56% (8.14%) 6.02%
EPS growth (last fiscal year) 71.56% (16.39%) 30.26%
Revenue growth, 5-year CAGR — 24.45% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NUVB OCUL Biotechnology median
Debt to equity 0.98 0.14 0.00
Current ratio 8.37 13.11 4.72
Net debt to EBITDA 2.26 2.51 0.96

Dividend

Metric NUVB OCUL Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NUVB OCUL Biotechnology median
Market cap 1.67b 1.62b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack